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Abstract 
Purpose: To study whether physical inactive women with a tendency to develop metabolic 
syndrome, have high levels of 17 -estradiol (E2) of importance for breast cancer risk. 
Methods: 204 healthy women of reproductive age were assessed for self-reported leisure-time 
physical activity (LPA), resting heart rate (HR), blood pressure (BP), anthropometry, and 
glucose, lipids and insulin (Norwegian EBBA study). E2 were measured in daily saliva samples 
throughout an entire menstrual cycle. A clustered metabolic risk score (zMS; total 
cholesterol:HDL-C-ratio, insulin resistance, total fat tissue, BP and triglycerides) was defined. 
Linear regression and linear mixed models were used and confounding factors were tested.  
Results: Physically active women had lower fat percentages (ptrend=0.003) and HRs 
(ptrend=0.003) than sedentary women. We estimated an increase in E2 of 1.27 pmol/L (95% CI, 
0.06-2.47) for each 11.7 beats/min (1SD) increase in HR, and this correspond to 7% change in 
mean concentration of E2 for the total group. Associations with E2 was also found for fat tissue, 
total cholesterol:HDL-C-ratio, insulin resistance and triglycerides. A dose–response relationship 
was observed among the three levels of LPA and HR, and zMS (ptrend=0.03 for LPA, ptrend=0.004 
for HR). Women in the highest tertile of the clustered metabolic risk score had average salivary 
E2 profiles that were markedly higher, throughout the cycle, than those of the other groups, with a 
cycle peak-day difference in E2 of 22–29%. 
Conclusion: LPA and HR were associated with metabolic risk score and this score was 
associated with daily level of 17 -estradiol, pointing to important biologic mechanisms operating 
between a sedentary lifestyle and increased breast cancer risk. 
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Introduction 
“Paragraph Number 1”  A sedentary lifestyle and high levels of estradiol are factors 
associated with increased breast cancer risk (34). The biological mechanisms underlying the 
relation between physical activity and breast cancer risk are complex and have not been fully 
identified (18). In contrast, estradiol is known to be associated with increased mitogenic and 
proliferative effect in breast cells (16) and has been identified as an important factor in the 
development and prognosis of breast cancer (18). However, reports on the association between 
estrogens and breast cancer risk among premenopausal women are sparse, partly because of the 
complexity of measuring hormonal levels throughout a menstrual cycle. Interestingly, in a recent 
publication from the Nurses’ Health Study II (7), the risk of breast cancer was more than doubled 
among premenopausal women in the highest quartile of the follicular free estradiol level 
compared with women in the lowest quartile. 
“Paragraph Number 2”  Even though the biological mechanisms that act in the association 
between physical activity and breast cancer risk are currently not fully outlined, there are several 
plausible mechanisms, including, among others, a suppressive effect of physical activity on 
ovarian steroid hormone production (21,23,25) and an effect on energy balance (12,18). The 
evidence for an inverse relationship between physical activity and breast cancer is stronger for 
postmenopausal than for premenopausal women (34). However, a number of case–control (2,11) 
and cohort studies (19,37) among various populations and on different continents, have observed 
a beneficial effect of physical activity on premenopausal breast cancer risk and on biological 
mechanisms important for breast cancer risk (22). The magnitude of the observed risk reduction 
has been, on average, between 20% and 40% for the most physically active women compared 
with the least active, and there is evidence for a dose–response relationship (18,28,34).       5
“Paragraph Number 3”   Moreover, physical activity is one of the few risk factors for breast 
cancer that can be modified; it is also a promising preventive measure for many other chronic 
diseases, because physical activity improves the metabolic risk profile (18,38). In addition, breast 
cancer has been linked to metabolic components including lipids, insulin, blood pressure, and 
tissue fat (35,36). In a cohort study, we demonstrated that low high-density lipoprotein-
cholesterol (HDL-C) is a potential marker of increased breast cancer risk among overweight 
women (14). In the Norwegian Energy Balance and Breast Cancer Aspect (EBBA) study (14), we 
confirmed the hypothesis that low HDL-C may be associated with increased levels of 17 -
estradiol (E2) throughout the entire menstrual cycle. Furthermore, in Poland, not that much 
westernized population yet and in a parallel study to our EBBA study, Jasienska et al. (23) 
observed habitual physical activity to be associated with lower levels of E2 throughout Polish 
women’s menstrual cycles. 
“Paragraph Number 4”  Since physical activity assessment is complex, a need exists to 
include objective measures of activity and energy expenditure when elucidating plausible 
biological mechanisms related to physical activity, E2, and later breast cancer risk. In the current 
study we have used resting heart rate (HR) and a set of metabolic factors related to the variation 
in physical activity as objective measurements. The aim of the present study was therefore (1) to 
study how self-reported leisure-time physical activity (LPA) and heart rate are related to levels of 
E2 and with the metabolic profile among premenopausal women, and (2) to investigate how a set 
of metabolic risk factors (fat tissue, BP [(systolic BP + diastolic BP)/2], insulin resistance, 
triglycerides and total cholesterol:HDL-C ratio) are associated with E2 throughout an entire 
menstrual cycle. 
 
Materials and methods       6
Participants and study design 
“Paragraph Number 5”   Women who participated in the cross-sectional EBBA study during 
2000–2002 were recruited through local media campaigns. A total of 204 6 women, 25–35 years 
of age, were included and met the following eligibility criteria: self-reported regular menstruation 
(normal cycle length: 22–38 days within the previous 3 months), no use of steroid contraceptives 
and no pregnancy or lactation over the previous 6 months, no history of gynecological disorders, 
and no chronic medical conditions (e.g. diabetes, hypo-/hyperthyroidism).  
 
Ethical considerations 
“Paragraph Number 6”   All participating women signed an informed consent form and the 
study was approved by the Regional Committee for Medical Research Ethics and the Norwegian 
Data Inspectorate. 
 
General questionnaires 
“Paragraph Number 7”   We used both self- and interviewer-administered questionnaires to 
collect general information, including education, reproductive history, previous use of hormonal 
contraceptives and lifestyle habits (smoking, alcohol). Recall aids including a lifetime calendar 
were used. We collected dietary data on 7 different week days during the menstrual cycle (days 
3–6 and 21–23) using a pre-coded food diary developed for the present study population, based 
on a validated pre-coded food diary (29). The average daily intake of energy and nutrients was 
computed using a food database and software system developed at the Department of Nutrition, 
University of Oslo, Norway (29).  
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“Paragraph Number 8” In the general questionnaire we asked about leisure time physical 
activity (LPA) over the last year. Leisure time was recorded and graded from 1 to 4 as follows:  
1 = low/sedentary activities, including reading, watching television, or other sedentary activities 
2 = moderate activities, including walking, bicycling, or physical activities for at least 4 hours a 
week 
3 = hard activities, including exercises to keep fit for at least 4 hours a week 
4 = very hard activities, defined as regular hard training or exercise for competition several times 
per week.  
“Paragraph Number 9”   The study participants made three subsequent visits in a fasting 
state during the collection period: first visit (days 1–5 of the menstrual cycle), second visit (days 
7–12), and third visit (days 22–25). The participants met on the first day possible, after onset of 
menstrual bleeding, for the first visit with clinical examinations, including height, weight, waist 
and hip circumference, resting HR, BP, and fasting blood sampling. All clinical procedures and 
measurements were conducted by trained nurses at the Department of Clinical Research, 
University Hospital North Norway (UNN), Tromsø, Norway, at a scheduled time (14).  
“Paragraph Number 10”  Heart rate (HR) and blood pressure (BP) were measured three times 
(PROPAQ 104), sitting in a resting position, with the mean of the final two measurements used in 
the analysis. 
“Paragraph Number 11”   Anthropometric measurements were taken with participants 
wearing light clothing and no footwear: height was measured to the nearest 0.5 cm and weight to 
the nearest 0.1 kg on an electronic scale. Waist circumference was measured in a horizontal line 
2.5 cm above the umbilicus; hip circumference was measured at the largest circumference, both 
measured to the nearest 0.5 cm.       8
“Paragraph Number 12”   Around the time of the second visit, participants underwent a 
whole-body scan using dual energy X-ray absorptiometry (DEXA – DPX-L 2288, Lunar 
Radiation Corporation, Madison, WI, USA), which was operated by our nurse; the percentage 
total fat tissue was estimated using standard Lunar software. 
“Paragraph Number 13”   Blood samples were drawn after overnight fasting (14). Serum 
concentrations
 of glucose, triglycerides, total cholesterol, HDL-C, and E2 were measured in fresh 
sera at the Department
 of Clinical Chemistry, UNN. Serum glucose was measured
 enzymatically 
by the hexokinase method, serum triglycerides
 were assayed by enzymatic hydrolysis with lipase, 
serum cholesterol
 was determined enzymatically using cholesterol esterase and
 cholesterol 
oxidase, with HDL-C quantified by a direct assay
 using polyethylene glycol-modified enzymes 
and dextran sulfate. Finally serum concentrations
 of insulin were measured at the
 Hormone 
Laboratory, Aker University Hospital, Oslo by RIA using
 kits from Linco Research, Inc. (St 
Charles, MO, USA) (14). 
 
Saliva hormone samples and analysis  
“Paragraph Number 14”   Women collected daily saliva samples at home for one entire 
menstrual cycle preferentially in the morning. They started on the first day of bleeding, according 
to previously established collection protocols developed at the Reproductive Ecology Laboratory 
at Harvard University, USA (31). 
“Paragraph Number 15”   E2 concentrations were measured in daily saliva samples for 20 
days (reverse cycle days  5 to  24) of the cycle using an 
125I-based radioimmunoassay (RIA) kit 
(#39100, Diagnostic Systems Laboratory, Webster, TX, USA), along with published 
modifications to the manufacturer’s protocol (20).       9
“Paragraph Number 16”   The sensitivity, and inter- and intra-assay variability of E2 have 
been described previously (13,14). Of the 4080 potential samples, improper collection or loss 
during the assay procedure resulted in a loss of 6.9% of daily E2 samples for the analyses. 
“Paragraph Number 17”   Before statistical analysis, all cycles were aligned to the day of 
ovulation, based on the identification of the E2 drop at the mid-cycle (day 0), which provides a 
reasonable estimate of the day of ovulation, according to published methods (31). The E2 values 
for 20 consecutive days during each woman’s cycle, aligned on day 0, were used in data analyses. 
Satisfactory identification of the mid-cycle E2 drop could not be made for 14 women and their 
cycles were not aligned. Overall average salivary E2 (mean E2) was calculated for all 204 women, 
whereas additional indices were calculated for the 190 women with aligned cycles. The following 
E2 indices were calculated: ‘mean E2’ (mean of day  10 to + 9), ‘mean follicular E2’ (mean of 
day  7 to  1), and ‘mean luteal E2’ (mean of day 0 to + 11). 
 
Statistical analysis  
“Paragraph Number 18”   In order to study E2 concentrations in relation to physical activity, 
heart rate and a clustered metabolic risk score, linear regression and linear mixed models were 
used (SAS version 9.1). 
“Paragraph Number 19”   As only 10 participants reported that they performed group 4 (very 
hard) activities, in the analyses we combined activity groups 3 and 4. Hence, the study population 
was divided into three groups of LPA (low, moderate and high activity).  
“Paragraph Number 20”  As indicator of insulin resistance, we used the HOMA-score, 
calculated as the product of fasting glucose concentration (in mmol/L) and fasting insulin 
concentration (in µU/mL) divided by the constant 22.5 (26).        10
“Paragraph Number 21”   To create clustered metabolic risk scores we computed the Z score 
(standard score) for selected individual risk factor variables associated with metabolic profile, 
broadly based on the World Health Organization definition of the metabolic syndrome. The Z 
score is calculated by subtracting the sample mean from the individual score (raw score), and 
dividing the difference by the sample standard deviation. It is negative when the raw score is 
below the sample mean and positive when the raw score is above the sample mean, and lower Z 
scores indicate a more favorable metabolic profile. The HOMA-score, fasting triglycerides and 
insulin were logarithmically transformed when used in the Z score, because of their skewed 
distribution. The Z scores of the individual risk factors were then summed to construct clustered 
risk scores. The five risk factors included in the main clustered risk score (zMS or z metabolic 
syndrome) were the ratio total cholesterol:HDL-C, logarithm of the HOMA-score, percentage of 
total fat as estimated from the DEXA scan, BP, and logarithm of the triglyceride levels. In 
parallel,
 we calculated a second clustered risk score containing the same variables without the 
obesity
 component (zMS-O).  
“Paragraph Number 22”   Age-adjusted linear regression analyses were used to study the 
associations of average salivary E2 concentration (overall, in the follicular and luteal phases of 
the menstrual cycle) and different variables related to the metabolic profile. We used a linear 
mixed model for repeated measures to study salivary E2 concentrations throughout the entire 
menstrual cycle in relation to HR, level of LPA, and the clustered risk scores. Different co-
variance structures were explored and the results using a heterogeneous Toeplitz method are 
presented. Dunnett’s method was used for multiple comparisons, with examination of residuals. 
Age was included as a co-variate in the final models. In addition, adjustment for birth weight, 
body mass index (BMI), energy intake, smoking, alcohol, previous use of hormonal       11
contraceptives, education, and age at menarche gave similar estimates and are not presented. 
Possible interactions were studied. 
“Paragraph Number 23”   E2 measurements at the start and end of the cycles have higher 
coefficients of variation and higher rates of missing as a result of variation in cycle length; we 
therefore included E2 measurements from day of cycle  10 to +9. Sample size estimation has 
shown that a sample size of 20-25 is sufficient to detect significant differences in indices of 
ovarian function between groups.  
 
Results 
“Paragraph Number 24”   The participating 204 healthy women of reproductive age were, on 
average,  30.7 years of age; 15.7% reported low LPA, 59.3% moderate LPA and 25.0% high 
LPA. Descriptive analyses were stratified by reported LPA (Table 1). Women with a high level 
of reported LPA had lower total fat percentage (ptrend=0.003), lower HR (ptrend=0.003), and 
tended to have a lower total cholesterol:HDL-C ratio (ptrend=0.09) and higher HDL-C 
(ptrend=0.12) than women with a more sedentary level of LPA (Table 1). There were no 
statistically significant differences in overall average salivary hormones or HOMA-score between 
the three groups. 
“Paragraph Number 25”   We studied estimated changes in overall average, follicular, and 
luteal salivary E2 concentrations by changes in the selected metabolic risk factor variables (Table 
2). We estimated that an increase (of 1 SD) in total fat tissue, HOMA-score, total 
cholesterol:HDL-C ratio, triglycerides and HR was associated with an age-adjusted increase in E2 
concentrations (Table 2). The mean daily saliva concentration of E2 throughout the menstrual 
cycle was 17.9 pmol/L (SD = 8.8 pmol/L) (data not presented). An age-adjusted increase in the       12
overall level of E2 of 1.27 pmol/L (95% confidence interval, CI, 0.06–2.47) was observed for 
each 11.7 beats/min (1SD) increase in heart rate, and this correspond to 7% (1.3 pmol/L of 
17.9 pmol/L) change in mean overall concentration of E2 for the total group. For each 0.8 (1 SD) 
increase in the total cholesterol:HDL-C ratio, the mean age-adjusted increase in overall E2 is 
2.46 pmol/L (95% CI, 1.26–3.66), which equals a 13.7% change in mean overall concentration of 
E2 for the total group.  
“Paragraph Number 26”  Figure 1A shows the association between the clustered metabolic 
score (zMS) and LPA. An inverse dose–response relationship was observed (ptrend=0.03). 
Likewise, figure 1B shows that zMS is directly related to HR in a dose-dependent manner 
(ptrend=0.004).  
“Paragraph Number 27”   We examined the average E2 concentrations by cycle day 
throughout the whole menstrual cycle by tertile of HR (Figure 2a, p between levels= 0.15) and at 
the three levels of LPA (Figure 2b, p between levels= 0.48), without finding a clear pattern, even 
when stratifying by birth weight (data not shown). No interaction was found between HR and day 
of E2 measurement (p=0.89) or level of activity and day of E2 measurement (p=0.18).  
“Paragraph Number 28”   In contrast, when we examined the E2 concentration by cycle day 
throughout the whole menstrual cycle, in tertiles of the clustered risk score, zMS, a clear pattern 
was observed; women in the highest tertile of the zMS had age-adjusted average salivary E2 
profiles that were markedly higher, throughout the cycle, than those of the other groups (Figure 
3). Using a linear mixed model for repeated measures, we examined how, in women in the group 
of the highest tertile of the zMS, the average E2 concentration by cycle day differed from that in 
the other groups of women described, and we observed significant age-adjusted differences for 
all comparisons (Figure 3; age-adjusted p values: tertile III–I, p=0.001; tertile III–II, p< 0.001).       13
The same pattern was observed when the obesity component was removed (i.e. zMS-O, not 
shown). 
“Paragraph Number 29”   When studying the peak day (the day before the drop day of the 
menstrual cycle), we observed that the mean peak-day levels of E2 in tertiles of zMS were as 
follows (Figure 3): lowest tertile 28.7 pmol/L, medium tertile 26.3 pmol/L, and highest tertile 
36.6 pmol/L (ptrend=0.001), which corresponds to a 21.6% and 28.7% difference between the 
highest tertile of the clustered metabolic risk score and the lowest and medium tertiles, 
respectively. 
 
Discussion 
“Paragraph Number 30”   Among 204 healthy premenopausal women we observed that those 
women with high leisure time physical activity (LPA) and women with lower heart rate (HR) had 
a more favorable clustered metabolic risk score, zMS, with a dose response relationship, than 
inactive women. In addition, we observed that this clustered risk score of metabolic factors was 
strongly associated with the daily level of free biologically active E2 throughout an entire 
menstrual cycle, with a cycle peak-day difference of 22–29% between the tertiles of zMS. 
“Paragraph Number 31”  The observation that healthy women of reproductive age in the 
current study showed a clear association between LPA and zMS, and that zMS were associated to 
levels of estradiol, is of great interest and support previously hypothesized biological 
mechanisms operating between physical activity and breast cancer  (14, 21, 24). Furthermore, 
western lifestyle, characterized by physical inactivity, is also associated with obesity and a 
metabolic imbalance, including unfavorable lipids, high blood pressure, and insulin resistance – 
factors that are also associated with increased breast cancer risk (15,18,30,37). Additionally,       14
several studies have observed a stronger protective effect of physical activity among lean women 
in comparisons with normal weighted women (21, 42). Furthermore, several recent studies 
provide support for the role of physical activity in the prevention of the metabolic syndrome 
(1,5). Randomized controlled trials have shown that exercise training has a mild or moderately 
favorable effect on many metabolic risk factors (27), whereas others have shown less association 
after controlling for obesity (17). Moreover, the metabolic syndrome is a cluster of risk factors 
that predisposes individuals to type 2 diabetes, and individuals with metabolic syndrome have an 
increased risk of all-cause mortality (27). 
Recently, the association between metabolic syndrome and its components (especially 
insulin), have been observed to predispose individuals to breast cancer. Hence, if physical 
activity can improve the metabolic risk profiles (3,38), it might indirectly reduce breast cancer 
risk. Importantly, we have recently pointed to sex hormones and insulin as important pathways 
towards the development of breast cancer (13). In the current study, we observed an association 
between the clustered metabolic risk score and the level of LPA, but the association was not there 
for all the single factors alone. There could be not only an additive effect, but also a 
multiplicative effect when several metabolic risk factors are put together in a cluster score based 
on biological effects. Another explanation may be that a clustered risk score may compensate for 
fluctuations in the single risk factors, or there could be less error variation in the clustered risk 
score compared with each single risk factor. However, this observation underlines the fact that 
physical activity may influence several factors often hypothesized (14,21) which, independently 
and/or together, influence the level of E2 and then lead to an increase in breast cancer risk. 
“Paragraph Number 33”   In our study, the clustered risk score, was positively associated with 
daily levels of E2 during the entire menstrual cycle: a high clustered metabolic risk score gave a       15
high level of E2. Interestingly, this observation was similar when the obesity component was 
excluded from the metabolic risk score, indicating that the protective effect of physical activity is 
not entirely mediated by changes in adiposity also supported by others (7). In a recent study, 
Ekelund et al. observed that an increase in physical activity is associated with reduced metabolic 
risk, independent of changes in fatness and fitness (6). However, in another study, Campbell et al. 
found that a 12-week aerobic exercise training intervention improved aerobic fitness and body 
composition, but did not alter the urinary estrogen metabolites in premenopausal women (4). 
These results regarding metabolites cannot be compared with our measurements of the free 
biologically active E2 throughout the entire menstrual cycle.  
“Paragraph Number 34”    Despite the HR not showing any clear pattern with level of E2 
throughout the menstrual cycle, when analyzing it as a single factor, it clearly associated with a 
clustering of metabolic factors  in the same way as leisure time activity. Previous studies have 
shown that heart rate has a clear association both with fitness and leisure time activity. These 
findings underline the role of heart rate as an objective measurement in clinical studies both in 
relation to metabolic profile and leisuretime activity (38). 
“Paragraph Number 35”   Current evidence supports an inverse relationship between physical 
activity and breast cancer risk (18), and one of the biologic mechanisms proposed to explain the 
protective effect is reduced exposure to E2 (2), based on the suppressive effect of physical 
activity on ovarian steroid hormones (18,23,25). Endurance training as well as general physical 
activity have been reported to give low levels of E2 (23,33); in a recent parallel study, a strong 
association was observed between habitual physical activity and level of E2 among 
premenopausal women in Poland (23). In addition, when stratifying by birth weight, Polish 
women who were relatively fat babies did not exhibit ovarian suppression in response to       16
moderate levels of physical activity at adulthood, in contrast to women who were skinnier babies 
(22). This suggests that ovarian responsiveness may depend on conditions during fetal life. In 
comparison, in the present study among Norwegian women, we observed that women with the 
most unfavourable metabolic profile (highest tertile zMS) had higher level of E2 throughout the 
menstrual cycle corresponding to a higher heart rate and lower leisure activity, compared to other 
women. This result suggests that ovarian responsiveness also may interact with normal 
physiology throughout adulthood of importance for premenopausal E2 levels throughout an entire 
menstrual cycle. In the present study, we did not observe a clear association between level of E2 
and level of LPA, or between level of E2 and HR as a single factor, even when stratifying by birth 
weight.  These findings suggest that Norwegian and Polish women may have different ovarian 
responsivenes to physical activity or that other factors may have an influence. 
“Paragraph Number 36”   The evidence for an inverse relationship between physical activity 
and breast cancer is stronger for postmenopausal than for premenopausal women (34). The 
women in our study were premenopausal, and there is no clear reason why physical inactivity is 
often less strongly related to increased risk of breast cancer among premenopausal women. The 
main source of E2 in premenopausal women is the ovaries, although it is also produced in adipose 
tissue. For postmenopausal women the main site for E2 production is adipose tissue. Thus, 
physical activity may influence premenopausal and postmenopausal breast cancer risk differently 
through different physiological and hormonal mechanisms, as seen with obesity (9). To elucidate 
in detail the influence of physical activity, it might be necessary to do subgroup analyses of birth 
characteristics, obesity, and parity which more often is performed and underlined as well as 
different aspects of the activity: type, intensity, frequencies, duration and age at exposure (10).        17
“Paragraph Number 37”   Our study has several strengths, including daily saliva sampling for 
estimation of daily E2 concentrations through an entire menstrual cycle. We used well-developed 
and validated methods and assays to characterize the women’s exposure to free, biologically 
active, ovarian steroids and performed comparisons of levels by aligned cycle days (31). This 
recommended approach, of examining all women at the same time during the menstrual cycle, is 
rarely achieved because of its logistic complexity (24). However, it is a major strength of this 
study, given the large intracycle fluctuations in levels of ovarian hormones and the wide inter-
individual variation in cycle length in menstruating women. Furthermore, salivary levels of E2 
was quite stable within participants over time (8). In addition, one trained nurse traced all the 
participants in the study and met them in the same clinical research department at a university 
hospital. This standardization enhanced the quality of our data and allowed us to sample all 
clinical variables within the same narrow frame of the cycle for each participant, using uniform 
procedures. To limit any potential influence of season, women did not participate during the 
winter months when there is no daylight (December and January). When adjusted for potential 
confounders such as age at menarche, parity, birth weight, energy intake, and use of alcohol, 
smoking, and previous oral contraceptives, we observed only small modifications of the 
interrelationships of clustered metabolic risk score and level of E2, which did not change the 
result.  
“Paragraph Number 38”   Assessment of physical activity is difficult and self-reported 
physical activity is less precise than objective measurements of physical activity. In addition, we 
used recorded LPA data over the last year, so the effect of physical activity in different time 
periods of life on E2 has not been examined in the current study. However, the self-reported LPA 
questionnaire that we used has previously been validated (32,39), found to be associated with HR       18
and to be a valid measure of physical fitness; 5869 women, 20 to 49 years of age, who both 
sustained high levels of physical activity and changed from sedentary to higher levels of physical 
activity, relative to sedentary women, improved their metabolic risk profiles (lipids, BMI) and 
HR (38), and the level of LPA and physical fitness, and HR and physical fitness were positively 
related (32).We used information about LPA, and not total activity, which includes habitual and 
occupational activity.  
 
Conclusion  
“Paragraph Number 39”   In conclusion, our data suggest that higher physical activity and 
lower heart rate are associated with a healthier metabolic risk profile, which furthermore is 
positively associated with levels of E2 throughout the entire menstrual cycle among healthy 
premenopausal women. These associations points to possible biological pathways operating in 
the inverse relationship between physical activity and breast cancer, but the interactions of these 
possible pathways are complex. Physical activity may influence the carcinogenesis of breast 
cancer by having a suppressive effect on ovarian steroid hormones as well as through reduced 
exposure to insulin and by reducing obesity.  
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Figure legends 
 
Figure 1 Mean (95% CI) clustered risk score (zMS) in (a) low, moderate and high activity and in (b) tertiles of  
resting heart rate. The clustered risk score is a sum of the Z score to total-cholesterol:HDL-C ratio, logarithm of 
triglycerides, blood pressure [(systolic BP + diastolic BP)/2], logarithm of HOMA-score and total percentage tissue 
fat (n = 204). 
 
Figur 2 Age-adjusted salivary 17 -estradiol concentrations by cycle day in women in (a) tertiles of the heart rate and 
(b) different levels of self-reported leisure-time physical activity. Linear mixed models for repeated measurements.  
 
Figure 3. Age-adjusted salivary E2 concentrations by cycle day in women in groups of clustered risk score, zMS 
[total-cholesterol:HDL-C ratio, logarithm of HOMA-score, total fat tissue % (DEXA), blood pressure [(systolic BP + 
diastolic BP)/2] and logarithm of triglycerides]. Linear mixed models for repeated measurements.  N=192. P<0.0001 
for differences in E2 concentration by cycle day of women in the highest tertile of zMS and cycles of women in the 
other tertiles (medium and lowest).  
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Table1: Characteristic of the study population by level of self-reported leisure time activity among premenopausal 
women: means (SD)* or proportions (from the Norwegian EBBA study [n = 204
†]) 
 
 
 
Low activity 
(n = 32) 
Moderate activity 
(n = 121) 
High activity 
(n = 51) 
p for 
trend‡ 
  Mean   (SD)  Mean  (SD)  Mean  (SD) 
Age (years)  30.98  (2.88)  30.81  (2.96)  30.32  (3.45)  0.31 
Age at menarche  13.16  (1.44)  13.03  (1.23)  13.29  (1.62)  0.55 
Energy intake (kJ/day)  7767.34  (1670.18)  8153.36  (1928.52)  8153.92  (1979.93)  0.43 
Education (total years)  16.08  (2.99)  15.61  (2.69)  17.11  (3.59)  0.05 
% with children  40.63    52.07    43.14    0.97 
Etnic minority, Sami (%)  3.13    9.92    5.88    0.83 
Current smokers (%)  28.13    23.97    13.73    0.10 
Alcohol (units/week)  2.33  (3.14)  2.69  (3.26)  3.72  (3.74)  0.05 
Body composition               
  BMI (kg/m
2)  24.90  (4.21)  24.38  (3.46)  24.14  (4.20)  0.39 
  Waist:hip ratio  0.78  (0.06)  0.77  (0.06)  0.77  (0.07)  0.40 
  Waist circumference (cm)  80.84  (10.65)  79.69  (8.87)  78.33  (11.32)  0.24 
  Total tissue fat (%)  36.38  (8.88)  34.61  (6.79)  31.63  (8.12)  0.003 
Clinical measurements               
  Heart rate (beats/min)  71.27  (11.48)  70.26  (11.12)  64.39  (11.43)  0.003 
  Systolic blood pressure (mmHg)  114.47  (10.67)  112.72  (10.36)  113.75  (13.34)  0.90 
  Diastolic blood pressure (mmHg)  71.36  (8.95)  70.78  (7.39)  70.84  (8.91)  0.81 
Saliva hormone concentrations (pmol/L)               
  Overall average Estradiol  17.92  (8.93)  17.20  (8.86)  19.55  (8.49)  0.29 
  Overall average Progesterone  121.24  (61.06)  129.31  (72.37)  137.75  (62.68)  0.28 
  Estradiol follicular index  18.70   (9.63)  16.91  (8.7)  19.72  (8.86)  0.45 
  Estradiol luteal index  18.97  (9.54)  18.20   (9.92)  19.70  (9.08)  0.66 
Serum concentrations§                
  Total cholesterol:HDL-cholesterol ratio  3.17  (0.71)  3.02  (0.81)  2.87  (0.83)  0.09 
  HDL-cholesterol (mmol/L)  1.45  (0.29)  1.55  (0.32)  1.57  (0.39)  0.12 
  Total cholesterol (mmol/L)  4.45  (0.67)  4.49  (0.77)  4.34  (0.88)  0.42 
  Fasting triglycerides (mmol/L)  0.90  (0.55)  0.86  (0.99)  0.87  (1.37)  0.93 
  Fasting glucose (mmol/L)  5.06  (0.54)  5.06  (0.62)  4.92  (0.42)  0.20 
  Insulin (µU/mL)  13.25  (10.20)  11.70  (6.35)  12.00  7.58)  0.55 
               
*SD, standard deviation. 
†Numbers may vary as a result of missing information. 
‡Linear regression or  
2 test. 
§Blood sampling first visit (days 1–5). 
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Table 2 Estimated changes* in salivary overall average 17 -estradiol (E2) with 95% confidence interval by 1 
standard deviation (SD) increase in the subcomponents of the clustered metabolic risk score (n = 204)
† 
 
 
Variable
‡  Mean (SD)  Overall average E2 
change 
Average E2 change 
(follicular index)§ 
Average E2 change 
(luteal index)§ 
                 
Total fat tissue, %  34.2   (7.6)  1.43  (0.23, 2.63)
a  1.40   (0.14, 2.66)
a  1.02  (-0.34, 2.38) 
Insulin resistance                 
  Glucose, mmol/L  5.02   (0.56)  0.84  (-0.39, 2.06)  0.93   (-0.33, 2.2)  0.44  (-0.90, 1.80) 
  Insulin, µU/mL  12.02   (7.35)  1.00  (-0.21, 2.21)  0.82  (-0.46, 2.10)  1.34  (-0.02, 2.72) 
  HOMA score**  2.67  (1.71)  1.25  (0.03, 2.46)
a  1.07  (-0.21, 2.35)  1.55  (0.19, 2.93)
a 
 Blood pressure                 
  Systolic BP, mmHg  113.3   (11.2)  0.12  (-1.10, 1.34)  0.07   (-1.23, 1.37)  0. 02  (-1.37, 1.41) 
  Blood pressure‡‡  92.07   (9.01)  -0.11  (-1.33, 1.10)  -0.15   (-1.44, 1.13)  -0.32  (-1.70, 1.06) 
Lipids                 
  Total C:HDL-C ratio   3.0   (0.8)  2.46  (1.26-3.66)
c  2.29   (1.01, 3.57) 
c  2.35  (0.97, 3.72)
 b 
  Triglycerides  0.77   (0.39)  1.62  (0.40, 2.85)
b  1.49   (0.23, 2.75) 
a  1.60
a  (0.25, 2.96) 
  Heart rate, beats/min   69.0   (11.5)  1.27  (0.06, 2.47)
a  1.29   (0.03, 2.55)
 a  1.31  (-0.04, 2.66) 
 
*Age adjusted regression coefficient and 95% confidence interval (CI). 
†Number may vary due to missing information 
‡Measurements at days 1–5 after onset of the menstrual cycle. 
§Includes women with aligned cycles only, n = 190. 
**As indicators of insulin resistance we used homeostasis model assessment (HOMA), calculated as the product of 
fasting glucose concentration (mmol/L) and fasting insulin concentration (µU/mL) divided by the constant 22.5. 
‡‡Blood pressure= [(systolic BP + diastolic BP)/2] 
ap < 0.05 
bp < 0.01 
cp < 0.001 
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